Form 4: Apyx Medical CEO Receives Stock Option Grant

Apyx Medical Corporation CEO Charles D. Goodwin II was granted 213,948 stock options as part of an equity incentive plan.

Summary

• CEO Charles D. Goodwin II received a grant of 213,948 stock options on June 11, 2026.
• The options have an exercise price of $4.65 per share.
• The grant vests ratably over a 36-month period, becoming fully exercisable on June 11, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Aligns executive compensation with long-term shareholder value through equity-based incentives.
• Vesting schedule encourages executive retention over a three-year period.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Market price volatility may impact the future value of the granted options.
• Potential for future dilution of equity if options are exercised.

Future Outlook

The options vest ratably over 36 months, indicating a long-term commitment to the company's performance through June 2029.

Management Comments

• No specific narrative comments provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants for executive leadership are standard practice in the medical device sector to ensure management interests are aligned with long-term corporate growth and shareholder returns.

Comparison to Industry Standards

• The use of a 36-month ratable vesting schedule is consistent with standard executive compensation packages in the small-cap medical technology industry.
• Granting options at the current market price is a standard governance practice to ensure the incentive is performance-based.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the granted options will occur monthly over the next 36 months.

Key Dates

Keywords

Apyx Medical, APYX, Form 4, Executive Compensation, Stock Options, Insider Transaction